225 related articles for article (PubMed ID: 27197631)
1. Autocrine-Based Selection of Drugs That Target Ion Channels from Combinatorial Venom Peptide Libraries.
Zhang H; Du M; Xie J; Liu X; Sun J; Wang W; Xin X; Possani LD; Yea K; Lerner RA
Angew Chem Int Ed Engl; 2016 Aug; 55(32):9306-10. PubMed ID: 27197631
[TBL] [Abstract][Full Text] [Related]
2. The voltage-gated potassium channel K
Tajti G; Wai DCC; Panyi G; Norton RS
Biochem Pharmacol; 2020 Nov; 181():114146. PubMed ID: 32653588
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel Kv1.3 targeting venom peptides by a single round of autocrine-based selection.
Liu Y; Zhang J; Wang R; Wu Y; Wang W; Xin X; Du M; Cao Y; Zhang H
Biochem Biophys Res Commun; 2019 Feb; 509(4):954-959. PubMed ID: 30648553
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life.
Edwards W; Fung-Leung WP; Huang C; Chi E; Wu N; Liu Y; Maher MP; Bonesteel R; Connor J; Fellows R; Garcia E; Lee J; Lu L; Ngo K; Scott B; Zhou H; Swanson RV; Wickenden AD
J Biol Chem; 2014 Aug; 289(33):22704-22714. PubMed ID: 24939846
[TBL] [Abstract][Full Text] [Related]
5. Tst26, a novel peptide blocker of Kv1.2 and Kv1.3 channels from the venom of Tityus stigmurus.
Papp F; Batista CV; Varga Z; Herceg M; Román-González SA; Gaspar R; Possani LD; Panyi G
Toxicon; 2009 Sep; 54(4):379-89. PubMed ID: 19500613
[TBL] [Abstract][Full Text] [Related]
6. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
7. Venom-derived peptide inhibitors of voltage-gated potassium channels.
Norton RS; Chandy KG
Neuropharmacology; 2017 Dec; 127():124-138. PubMed ID: 28689025
[TBL] [Abstract][Full Text] [Related]
8. Peptide blockers of K
Chandy KG; Norton RS
Curr Opin Chem Biol; 2017 Jun; 38():97-107. PubMed ID: 28412597
[TBL] [Abstract][Full Text] [Related]
9. Treating autoimmune disorders with venom-derived peptides.
Shen B; Cao Z; Li W; Sabatier JM; Wu Y
Expert Opin Biol Ther; 2017 Sep; 17(9):1065-1075. PubMed ID: 28695745
[TBL] [Abstract][Full Text] [Related]
10. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
11. The Kv1.3 K
Varga Z; Tajti G; Panyi G
Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500
[TBL] [Abstract][Full Text] [Related]
12. Conformational exchange in the potassium channel blocker ShK.
Iwakawa N; Baxter NJ; Wai DCC; Fowler NJ; Morales RAV; Sugase K; Norton RS; Williamson MP
Sci Rep; 2019 Dec; 9(1):19307. PubMed ID: 31848433
[TBL] [Abstract][Full Text] [Related]
13. A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.
Takacs Z; Toups M; Kollewe A; Johnson E; Cuello LG; Driessens G; Biancalana M; Koide A; Ponte CG; Perozo E; Gajewski TF; Suarez-Kurtz G; Koide S; Goldstein SA
Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22211-6. PubMed ID: 20007782
[TBL] [Abstract][Full Text] [Related]
14. Venom-derived peptides inhibiting Kir channels: Past, present, and future.
Doupnik CA
Neuropharmacology; 2017 Dec; 127():161-172. PubMed ID: 28716449
[TBL] [Abstract][Full Text] [Related]
15. Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes.
Gurrola GB; Hernández-López RA; Rodríguez de la Vega RC; Varga Z; Batista CV; Salas-Castillo SP; Panyi G; del Río-Portilla F; Possani LD
Biochemistry; 2012 May; 51(19):4049-61. PubMed ID: 22540187
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.
Murray JK; Qian YX; Liu B; Elliott R; Aral J; Park C; Zhang X; Stenkilsson M; Salyers K; Rose M; Li H; Yu S; Andrews KL; Colombero A; Werner J; Gaida K; Sickmier EA; Miu P; Itano A; McGivern J; Gegg CV; Sullivan JK; Miranda LP
J Med Chem; 2015 Sep; 58(17):6784-802. PubMed ID: 26288216
[TBL] [Abstract][Full Text] [Related]
17. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.
Pennington MW; Chang SC; Chauhan S; Huq R; Tajhya RB; Chhabra S; Norton RS; Beeton C
Mar Drugs; 2015 Jan; 13(1):529-42. PubMed ID: 25603346
[TBL] [Abstract][Full Text] [Related]
18. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
Rashid MH; Heinzelmann G; Huq R; Tajhya RB; Chang SC; Chhabra S; Pennington MW; Beeton C; Norton RS; Kuyucak S
PLoS One; 2013; 8(11):e78712. PubMed ID: 24244345
[TBL] [Abstract][Full Text] [Related]
19. Identification of a new specific Kv1.3 channel blocker, Ctri9577, from the scorpion Chaerilus tricostatus.
Xie S; Feng J; Yu C; Li Z; Wu Y; Cao Z; Li W; He X; Xiang M; Han S
Peptides; 2012 Jul; 36(1):94-9. PubMed ID: 22580271
[TBL] [Abstract][Full Text] [Related]
20. A selective blocker of Kv1.2 and Kv1.3 potassium channels from the venom of the scorpion Centruroides suffusus suffusus.
Corzo G; Papp F; Varga Z; Barraza O; Espino-Solis PG; Rodríguez de la Vega RC; Gaspar R; Panyi G; Possani LD
Biochem Pharmacol; 2008 Oct; 76(9):1142-54. PubMed ID: 18786511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
